Renal hemodialysis and maternal serum triple analyte screening.
The obstetrical management of women with renal disease is complicated and associated with increased fetal and maternal morbidity. However, maternal serum screening is an integral part of obstetrical care and should be offered to all women. We found that maternal serum levels of a-fetoprotein and human chorionic gonadotropin did not significantly change as a result of hemodialysis, whereas levels of unconjugated estriol were markedly decreased following hemodialysis. Maternal serum screening should be limited to alpha-fetoprotein analysis in women undergoing hemodialysis until the effects of hemodialysis on all serum analytes are better delineated.
Shulman
L P
LP
Department of Obstetrics and Gynecology, University of Tennessee at Memphis, 38103-2896, USA.
Briggs
R
R
Phillips
O P
OP
Friedman
S A
SA
Sibai
B
B
D000328:Adult; D006063:Chorionic Gonadotropin / Q000097:blood*; D002908:Chronic Disease; D004964:Estriol / Q000097:blood*; D005260:Female; D005921:Glomerulonephritis / Q000097:blood / Q000628:therapy*; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood*; D006435:Renal Dialysis; D000509:alpha-Fetoproteins / Q000032:analysis*
D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D004964:Estriol